Lobbying Activity Report

4636-52122

Organization: Apotex Inc.
Associated registration: 9348-4636-7
Lobbying Activity date: 2026-06-09
Arranged a meeting: No
Posted date: 2026-07-15

In-house lobbyists who participated in the lobbying activity: Matthew Southcott
Chris Fournier
Senior Public Office Holders who were lobbied in this activity: Susan Bouma, Executive Director
Therapeutic Assessment & Access, Health

Lanlin Bu, Governance and Planning Analyst
TCR - Transformation & Corporate Reporting, Health

John Capelli, Executive Director
Pharmaceutical Policy, Legislation & Engagement Branch, Health

Chris Ingram, Director
Therapeutic Assessment and Access Branch, Health

Sarah Pugh, Executive Director
Integrated Health Services, Planning & Systems, Health

Ian Rongve, ADM
Strategic Innovation, Health
 
Subject Matter of the Lobbying Activity
Specific Topics of Lobbying Communications Intended Outcomes Associated Subject Matters
Ongoing interactions related to increased and sustainable utilization of cost-saving generic and biosimilar medicines, and a predictable and viable business environment for generic medicines.
  • Development or enactment of any regulation, including the enactment of a regulation for the purposes of amending or repealing a regulation
  • Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
  • Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity
 Government Procurement, Health
 
Senior officer who filed this Lobbying Activity Report: Martin Arès
 
The above name is that of the most senior paid officer who is responsible for filing a Lobbying Activity Report for the organization (the Designated Filer), whether that person participated in this lobbying activity or not.
Date Modified: